We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Technologies, Inc. (A - Free Report) recently announced that it has successfully closed the acquisition of the business assets of ULTRA Scientific, Inc.
The deal was announced in May but its financial terms were not disclosed. The buyout will aid Agilent’s chemical standards business and further help in providing complete workflow solutions to customers.
Coming to share price, shares of Agilent have slightly underperformed its industry on a year-to-date basis. The stock has registered a gain of 2.99% compared with the industry’s growth of 14.18% in the said period.
Deal Details
As revealed, Ultra Scientific is a manufacturer and supplier of certified reference materials, organic and inorganic standards, calibration standards, IQ/OQ/PQ and quality control check standards. The solutions are used in key end markets including environmental, food, forensics, pharmaceutical, chemical and energy, and academia and government by laboratory professionals.
The deal will strengthen Agilent’s certified reference materials and chemical standards business portfolio. In addition, the deal will provide complete workflow solutions across Agilent's instrument platforms, thereby meeting customer needs in a better way. The deal will also boost the company’s recurring revenues.
Acquisitions — Key Catalyst
Over the past few years, strategic acquisitions have played an important role in shaping Agilent’s growth trajectory.
Continuous strategic acquisitions should support Agilent to expand product offerings, strengthen its footprint in the international markets and build customer base.
However, these acquisitions will likely keep Agilent’s operating margins under pressure, as it requires a significant amount of new investments.
Currently, Agilent carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same industry include Groupon (GRPN - Free Report) , IAC/InterActiveCorp (IAC - Free Report) and Ctrip.com International, Ltd. . While Groupon and IAC/InterActiveCorp sport a Zacks Rank #1 (Strong Buy), Ctrip.com holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth for Groupon, IAC/InterActiveCorp and Ctrip.com is currently projected to be 6.5%, 7.5% and 16%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Agilent Acquires ULTRA Scientific Assets, Expands Portfolio
Agilent Technologies, Inc. (A - Free Report) recently announced that it has successfully closed the acquisition of the business assets of ULTRA Scientific, Inc.
The deal was announced in May but its financial terms were not disclosed. The buyout will aid Agilent’s chemical standards business and further help in providing complete workflow solutions to customers.
Coming to share price, shares of Agilent have slightly underperformed its industry on a year-to-date basis. The stock has registered a gain of 2.99% compared with the industry’s growth of 14.18% in the said period.
Deal Details
As revealed, Ultra Scientific is a manufacturer and supplier of certified reference materials, organic and inorganic standards, calibration standards, IQ/OQ/PQ and quality control check standards. The solutions are used in key end markets including environmental, food, forensics, pharmaceutical, chemical and energy, and academia and government by laboratory professionals.
The deal will strengthen Agilent’s certified reference materials and chemical standards business portfolio. In addition, the deal will provide complete workflow solutions across Agilent's instrument platforms, thereby meeting customer needs in a better way. The deal will also boost the company’s recurring revenues.
Acquisitions — Key Catalyst
Over the past few years, strategic acquisitions have played an important role in shaping Agilent’s growth trajectory.
Continuous strategic acquisitions should support Agilent to expand product offerings, strengthen its footprint in the international markets and build customer base.
However, these acquisitions will likely keep Agilent’s operating margins under pressure, as it requires a significant amount of new investments.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. Price and Consensus | Agilent Technologies, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same industry include Groupon (GRPN - Free Report) , IAC/InterActiveCorp (IAC - Free Report) and Ctrip.com International, Ltd. . While Groupon and IAC/InterActiveCorp sport a Zacks Rank #1 (Strong Buy), Ctrip.com holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth for Groupon, IAC/InterActiveCorp and Ctrip.com is currently projected to be 6.5%, 7.5% and 16%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>